Erdosteine

Erdosteine inhibits lipopolysaccharide (LPS) -induced NF-κB activation[1][2]. Erdosteine has muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant effects[3].

Product Specifications

CAS Number

[84611-23-4]

Product Name Alternative

RV 144

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bacterial; NF-κB

Type

Reference compound

Related Pathways

Anti-infection; NF-κB

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Infection; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Erdosteine.html

Purity

99.83

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 6.67 mg/mL (ultrasonic)

Smiles

O=C(O)CSCC(NC(CCS1)C1=O)=O

Molecular Formula

C8H11NO4S2

Molecular Weight

249.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Park JS, et al. Anti-inflammatory Effect of Erdosteine in Lipopolysaccharide-Stimulated RAW 264.7 Cells. Inflammation. 2016 Aug;39 (4) :1573-81.|[2]Oktar S, et al. Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice. Toxicol Ind Health. 2010 Aug;26 (7) :433-8.|[3]Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment